Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome

Metabolism: Clinical and Experimental

Volumn 59, Issue 3, 2010, Pages 305-313

  Unek, Ilkay Tugba ^a   Bayraktar, Firat ^a   Solmaz, Dilek ^a   Ellidokuz, Hulya ^a   Yuksel, Faize ^a   Sisman, Ali Riza ^a   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; AGED; AGED, 80 AND OVER; ANTHROPOMETRY; BLOOD CELL COUNT; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CD40 LIGAND; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PLATELET COUNT;

EID: 76649125265     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.04.034     Document Type: Article

References (71)

1. Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 29 (2003) 6S19-6S27
2. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
3. Ginsberg H.N. Treatment for patients with the metabolic syndrome. Am J Cardiol 91 Suppl (2003) 29E-39E
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 19 (2001) 2486-2497
5. Despres J.P., and Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 5 (1994) 274-289
6. Mitchell B.D., Kammerer C.M., Mahaney M.C., et al. Genetic analysis of the IRS. Pleiotropic effects of gene influencing insulin levels on lipoprotein and obesity measures. Arterioscler Thromb Vasc Biol 16 (1996) 281-288
7. Liese A.D., Mayer-Davis E.J., Tyroler H.A., et al. Familial components of the multiple metabolic syndrome: the ARIC Study. Diabetologia 40 (1997) 963-970
8. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24 (2003) 278-301
9. Haffner S.M. Insulin resistance, inflammation, and prediabetic state. Am J Cardiol 92 Suppl (2003) 18J-26J
10. Haverkate F., Thompson S.G., Pyke S.D.M., et al. Production of C-reactive protein and risk of coronary events in stable angina. Lancet 349 (1997) 462-466
11. Pradhan A.D., and Ridker P.M. Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. Eur Heart J 23 (2002) 831-834
12. Yeh E.T.H., Anderson H.V., Pasceri V., and Willerson J.T. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104 (2001) 974-975
13. Pasceri V., Willerson J.T., and Yeh E.T.H. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
14. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
15. Koenig W., Sund M., Fröhlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 99 (1999) 237-242
16. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 107 (2003) 391-397
17. Frohlich M., Imhoe A., Berg G., et al. Association between C-reactive protein and features of metabolic syndrome. Diabetes Care 23 (2000) 1835-1839
18. Schönbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58 (2001) 4-43
19. Schönbeck U., Mach F., and Libby P. CD154 (CD40 ligand). IJBCB 32 (2000) 687-693
20. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet derived CD40 ligand. Circulation 106 (2002) 896-899
21. Schönbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
22. Phipps R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 97 (2000) 6930-6932
23. Desideri G., and Feri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA 289 (2003) 1781-1782
24. Garlichs C.D., John S., Schmeiβer A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
25. Cipollone F., Mezzetti A., Porreca E., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Circulation 106 (2002) 399-402
26. Semb A.G., van Wissen S., Ueland T., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Cardiol 41 (2003) 275-279
27. Jinchuan Y., Zonggui W., Jinming C., et al. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clinica Chimica Acta 339 (2004) 85-90
28. Varo N., Vicent D., Libby P., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. Circulation 107 (2003) 2664-2669
29. Schernthaner G.H., Kopp H.P., Krzyzanowska K., et al. Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. Eur J Clin Invest 36 (2006) 395-401
30. Guldiken S., Demir M., Arikan E., et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 119 (2007) 79-84
31. Aukrust P., Müler F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Circulation 100 (1999) 614-620
32. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108 (2003) 1049-1052
33. Garlichs C.D., Eskafi S., Raaz D., et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD 154 on platelets. Heart 86 (2001) 649-655
34. Peng D.Q., Zhao S.P., Li Y.F., et al. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta 319 (2002) 19-26
35. Schönbeck U., Varo N., Libby P., et al. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
36. Angelico F., Alessandri C., Ferro D., et al. Enhanced soluble CD40L in patients with the metabolic syndrome: relationship with in vivo thrombin generation. Diabetologia 49 (2006) 1169-1174
37. Gokulakrishnan K., Deepa R., Mohan V., et al. Soluble p-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metab Clin Exp 55 (2006) 237-242
38. Lee W.L., Lee W.J., Chen Y.T., et al. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metabolism 55 (2006) 1029-1034
39. Natal C., Restituto P., Inigo C., et al. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab 93 (2008) 2319-2327
40. American Diabetes Association A. Diabetes Care 28 Suppl (2005) S37-S42
41. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, Insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
42. Piche M.E., Lemieux S., Weisnagel S.J., et al. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 96 (2005) 92-97
43. Hak A.E., Stehouwer C.D.A., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19 (1999) 1986-1991
44. McLaughlin T., Abbasi F., Lamendola C., et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106 (2002) 2908-2912
45. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women. JAMA 289 (2003) 1799-1804
46. Davi G., Guagnano M.T., Ciabattoni G., et al. Platelet activation in obese women. JAMA 288 (2002) 2008-2014
47. Pickup J.C., and Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 41 (1998) 1241-1248
48. Stolar M.W., and Chilton R.J. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 25 Suppl B (2003) B4-B31
49. Ross R., Aru J., Freeman J., Hudson R., and Janssen I. Abdominal adiposity and insulin resistance in obese men. Am J Physiol Endocrinol Metab 282 (2002) E657-E663
50. Despres J.P. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9 (1993) 452-459
51. Park K.S., Rhee B.D., Lee K.U., et al. Intra-abdominal fat is associated with decreased insulin sensitivity in healthy young men. Metabolism 40 (1991) 600-603
52. Pignatelli P., Sanguigni V., Lenti L., et al. gp91phox-dependent expression of platelet CD40 ligand. Circulation 110 (2004) 1326-1329
53. Lim H.S., Blann A.D., and Lip G.Y. Soluble CD40 ligand, soluble p-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109 (2004) 2524-2528
54. Azar R.R., Badaoui G., Sarkis A., et al. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 95 (2005) 236-240
55. Choi K.M., Lee J., Lee K.W., et al. Comparison of serum concentrations of C-reactive protein, TNF-α, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 64 (2004) 99-106
56. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88 (2003) 2399-2403
57. Johnson D., Prud'homme D., Despres J.P., et al. Relation of abdominal obesity to hyperinsulinemia and high blood pressure in men. Int J Obes Relat Metab Disord 16 (1992) 881-890
58. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques. Circulation 101 (2000) 1372-1378
59. Dagenais G.R., Pogue J., Fox K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006) 581-588
60. Watanabe T., Barker T.A., and Berk B.C. Angiotensin II and endothelium: diverse signals and effects. Hypertension 45 (2005) 163-169
61. Han S.H., Koh K.K., Quon M.J., et al. The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 190 (2007) 205-211
62. Koh K.K., Quon M.J., Han S.H., et al. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1 + 2 in patients with type 2 diabetes. Atherosclerosis 194 (2007) 230-237
63. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 29 (2006) 195-201
64. Koh K.K., Quon M.J., Han S.H., et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 108 (2006) 96-100
65. Nannizzi-Alaimo L., Alves V.L., and Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107 (2003) 1123-1128
66. Hermann A., Rauch B.H., Braun M., et al. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12 (2001) 74-82
67. Steinhubl S.R., Badimon J.J., Bhatt D.K., et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 12 (2007) 113-122
68. Wang T.D., Chen W.J., Lin J.W., et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170 (2003) 315-323
69. Santini E., Madec S., Corretti V., et al. Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients. J Endocrinol Invest 31 (2008) 660-665
70. Chu C.S., Lee K.T., Lee M.Y., et al. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol 61 (2006) 263-269
71. Chu C.S., Lee K.T., Lee M.Y., et al. Effects of rosiglitazone alone and in combination with Atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 97 (2006) 646-650